Wall Street analysts predict that Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) will report $10.34 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Intellia Therapeutics’ earnings, with the highest sales estimate coming in at $17.50 million and the lowest estimate coming in at $5.70 million. Intellia Therapeutics posted sales of $6.45 million during the same quarter last year, which suggests a positive year over year growth rate of 60.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Intellia Therapeutics will report full year sales of $48.24 million for the current financial year, with estimates ranging from $5.03 million to $145.80 million. For the next year, analysts expect that the company will post sales of $42.96 million, with estimates ranging from $5.50 million to $120.00 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last announced its earnings results on Thursday, February 24th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by ($0.18). The firm had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $7.83 million. Intellia Therapeutics had a negative net margin of 810.49% and a negative return on equity of 33.61%. The company’s revenue was up 95.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.69) EPS.
Shares of NASDAQ:NTLA traded down $1.76 during trading hours on Friday, hitting $61.24. 23,008 shares of the company’s stock traded hands, compared to its average volume of 1,155,924. The business has a fifty day moving average price of $78.83 and a 200-day moving average price of $104.86. Intellia Therapeutics has a 1 year low of $56.47 and a 1 year high of $202.73.
Several large investors have recently added to or reduced their stakes in the company. Morgan Stanley boosted its position in shares of Intellia Therapeutics by 38.1% in the 2nd quarter. Morgan Stanley now owns 697,723 shares of the company’s stock worth $112,968,000 after purchasing an additional 192,393 shares in the last quarter. Wolff Wiese Magana LLC boosted its holdings in Intellia Therapeutics by 21.5% in the third quarter. Wolff Wiese Magana LLC now owns 1,464 shares of the company’s stock worth $196,000 after acquiring an additional 259 shares in the last quarter. Strs Ohio grew its stake in shares of Intellia Therapeutics by 4.3% during the third quarter. Strs Ohio now owns 17,000 shares of the company’s stock worth $2,280,000 after acquiring an additional 700 shares during the last quarter. Spire Wealth Management increased its holdings in shares of Intellia Therapeutics by 125.0% during the third quarter. Spire Wealth Management now owns 450 shares of the company’s stock valued at $60,000 after acquiring an additional 250 shares in the last quarter. Finally, Capital Advisors Inc. OK raised its position in shares of Intellia Therapeutics by 2,006.9% in the 3rd quarter. Capital Advisors Inc. OK now owns 44,245 shares of the company’s stock valued at $5,935,000 after purchasing an additional 42,145 shares during the last quarter. Institutional investors and hedge funds own 86.60% of the company’s stock.
Intellia Therapeutics Company Profile (Get Rating)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
- Get a free copy of the StockNews.com research report on Intellia Therapeutics (NTLA)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.